Journal of Clinical and Aesthetic Dermatology

Updates on Psoriasis & Cutaneou Oncology

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link:

Contents of this Issue


Page 39 of 43

Immunother. 2008;57(8):1241–1251. 138. schlaak M, simon Jc. topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid--pilot study. J Dtsch Dermatol Ges. 2010;8(3):174–178. 139. stockfleth e, Kerl H, Zwingers t, Willers c. low-dose 5- guorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165(5):1101–1108. 140. stockgeth e, Zwingers t, Willers c. recurrence rates and patient assessed outcomes of 0.5% 5-guorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol. 2012;22(3):370–374. 141. stockgeth e, von Kiedrowski r, Dominicus r, et al. eecacy and safety of 5-guorouracil 0.5%/salicylic acid 10% in the feld-directed treatment of actinic keratosis: a Phase iii, randomized, double-blind, vehicle-controlled trial. Dermatol Ther (Heidelb). 2017;7(1):81–96. 142. Hanahan D. rethinking the war on cancer. Lancet. 2014;383(9916):558–563. 143. schmitt Jv, chinem vP, Marques Me, Miot Ha. increase in the incidence of basal cell carcinoma in a university hospital between 1999 and 2009. An Bras Dermatol. 2011;86(2):375–377. 144. van Hattem s, aarts MJ, louwman WJ, et al. increase in basal cell carcinoma incidence steepest in individuals with high socioeconomic status: results of a cancer registry study in the netherlands. Br J Dermatol. 2009;161(4):840–845. 145. asgari MM, Modet HH, ray Gt, Quesenberry cP. trends in basal cell carcinoma incidence and identifcation of high- risk subgroups, 1998-2012. JAMA Dermatol. 2015;151(9):976–981. 146. american cancer society. Key statistics for basal and squamous cell skin cancers. 10 May 2016; cell-skin-cancer/about/key-statistics.html. accessed 7 May 2017. 147. Walko cM, lindley c. capecitabine: a review. Clin Ther. 2005;27(1):23–44. 148. Weiss JM, Bagley s, Hwang Wt, et al. capecitabine and lapatinib for the frst-line treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer. 2016;122(15):2350–2355. 149. Marmur es, schmults cD, Goldberg DJ. a review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg. 2004;30(2 Pt 2):264–271. 150. Dragieva G, Hafner J, Dummer r, et al. topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation. 2004;77(1):115–121. 151. Gorlin rJ. nevoid basal-cell carcinoma syndrome. Medicine (Baltimore). 1987;66(2):98–113. 152. Bale ae, yu KP. the hedgehog pathway and basal cell carcinomas. Hum Mol Genet. 2001;10(7):757-762. 153. oserod ar, shieh s, frawley nP, et al. treatment of diduse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch Dermatol. 2005;141(1):60–67. 154. Zeitouni nc, sunar u, rohrbach DJ, et al. a prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer. Dermatol Surg. 2014;40(12):1390–1394. 155. schmitz l, novak B, Hoeh aK, luebbert H, Dirschka t. epidermal penetration and protoporphyrin ix formation of two diderent 5-aminolevulinic acid formulations in ex vivo human skin. Photodiagnosis Photodyn Ther. 2016;14:40–46. 156. ameluz [assessment report]. european Medicines agency committee for Medicinal Products for Human use; 15 Dec 2016. rary/ePar_-_assessment_report_- _variation/human/002204/Wc500222131.pdf 157. Hengge ur, schaller J. successful treatment of invasive squamous cell carcinoma using topical imiquimod. Arch Dermatol. 2004;140(4):404–406. 158. Kossard s. treatment of large facial Bowen's disease: case report. Clin Exp Dermatol. 2003;28 suppl 1:13–15. 159. ondo al, Mings sM, Pestak rM, shanler sD. topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-guorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol. 2006;55(6):1092– 1094. 160. McKay KM, sambrano Bl, fox Ps, Bassett rl, chon s, Prieto vG. thickness of superfcial basal cell carcinoma (sBcc) predicts imiquimod eecacy: a proposal for a thickness-based defnition of sBcc. Br J Dermatol. 2013;169(3):549–554. 161. love We, Bernhard JD, Bordeaux Js. topical imiquimod or guorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145(12):1431–1438. 162. Bettencourt Ms. treatment of superfcial basal cell carcinoma with ingenol mebutate gel, 0.05%. Clin Cosmet Investig Dermatol. 2016;9:205–209. 163. Kirby Js, Miller cJ. intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol. 2010;63(4):689–702. 164. arpey c, annest n, tucker s, rapini r, Macfarlane D. intralesional and Perilesional treatment of skin cancers. Skin Cancer Management: Springer Science + Business Media, LLC; 2010:57–76. 165. longo c, ragazzi M, rajadhyaksha M, et al. in vivo and ex vivo confocal Microscopy for Dermatologic and Mohs surgeons. Dermatol Clin. 2016;34(4):497–504. 166. shin tM, etzkorn Jr, sobanko Jf, et al. clinical factors associated with subclinical spread of in situ melanoma. J Am Acad Dermatol. 2017;76(4):707–713. 167. shin tM, shaikh Wr, etzkorn Jr, et al. clinical and pathologic factors associated with subclinical spread of invasive melanoma. J AM Acad Dermatol. 2017;76(4):714–721. 168. Moyer Js, rudy s, Boonstra Ps, et al. eecacy of staged excision with permanent section margin control for cutaneous head and neck melanoma. JAMA Dermatol (Chicago, Ill). 2017;153(3):282–288. 169. friedman BJ, Pimentel JD, ozog DM. achieving optimal en face tissue sections during staged lentigo maligna excisions: a novel technique. Dermatol Surg. 2015;41(11):1332–1335. 170. Bricca G, Brodland D, Zitelli J. immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg. 2004;30:403–408. 171. christensen Kn, Hochwalt Pc, Hocker tl, et al. comparison of Mitf and melan-a immunohistochemistry during mohs surgery for lentigo maligna-type melanoma in situ and lentigo maligna melanoma. Dermatol Surg. 2016;42(2):167–175. 172. nghiem Pt, Bhatia s, lipson eJ, et al. PD-1 Blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–2552. 173. iyer JG, Blom a, Doumani r, et al. response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294–2301. 174. lebbe c, Becker J, Grob J. Diagnosis and treatment of Merkel cell carcinoma. european consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51:2396– 2403. 175. Kaufman Hl, russell J, Hamid o, et al. avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–1385. 176. Winkler JK, Dimitrakopoulou-strauss a, sachpekidis c, enk a, Hassel Jc. ipilimumab has eecacy in metastatic Merkel cell carcinoma: a case series of fve patients. J Eur Acad Dermatol Venereol. 2017. 177. Pariser DM, Houlihan a, ferdon MB, Berg Je. randomized vehicle-controlled study of short drug incubation aminolevulinic acid photodynamic therapy for actinic keratoses of the face or scalp. Dermatol Surg. 2016;42(3):296–304. 178. nissen cv1, Heerfordt iM, Wiegell sr, Mikkelsen cs, Wulf Hc. Pretreatment with 5-guorouracil cream enhances the eecacy of daylight-mediated photodynamic therapy for actinic keratosis. Acta Derm Venereol. 2017;97(5):617–621. 179. Willey a, anderson rr, sakamoto fH. temperature- modulated photodynamic therapy for the treatment of actinic keratosis on the extremities: a one-year follow- up study. Dermatol Surg. 2015;41(11):1290–1295. 180. ozog DM, rkein aM, fabi sG, et al. Photodynamic therapy: a clinical consensus guide. Dermatol Surg. 2016;42(7):804–827. 181. Martin GM. in-oece painless aminolevulinic acid photodynamic therapy: a proof of concept study and clinical experience in more than 100 patients. J Clin Aesthet Dermatol. 2016;9(2):19–26. 182. reinhold u, Dirschka t, ostendorf r, et al. a randomized, double-blind, phase iii, multicentre study to evaluate the safety and eecacy of Bf-200 ala (ameluz((r)) ) vs. placebo in the feld-directed treatment of mild-to- moderate actinic keratosis with photodynamic therapy (PDt) when using the Bf-rhodoleD((r)) lamp. Br J S40 P r o c e e D i n G s JCAD jOUrnAl Of ClInICAl And AEsthEtIC dErMAtOlOgy september 2017 • volume 10 • number 9 • supplement

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Updates on Psoriasis & Cutaneou Oncology